Inventor · disambiguated record
Leonardo Viana Nicacio
Also filed as: NICACIO LEONARDO V · NICACIO LEONARDO VIANA
3 granted patents·6 pending applications·0 citations·filing 2019–2024
39Inventor score
Files withGENMAB AS9
Top patents by PatentIndex Score
9 records- 0169US2025066507A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2024·Application pending·0 cites
- 0256US12246025B2Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Mar 11, 2025·0 cites·25 claims
- 0354US2021107980A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Application pending·0 cites
- 0448US12453781B2Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Oct 28, 2025·0 cites·36 claims
- 0548US2021308208A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 0646US2022387485A1Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 0745US2021030888A1Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 0844US2023027495A1Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2020·Application pending·0 cites
- 0938US12324841B2Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugateGENMAB AS·Filed 2019·Granted Jun 10, 2025·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Leonardo Viana Nicacio files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →